Polaryx Therapeutics Q3 2026 Results: Net Loss of $3.33M, Loss Widens
Polaryx Therapeutics reported a net loss of $7.3 million for the nine months ended September 30, 2026, compared to $7.5 million in the prior year period. The company maintains a going concern warning due to recurring losses and negative operating cash flows, though it successfully raised $9.8 million through common stock issuances during the period.
- Key figure
- Net loss $3.33M